biostudies-literatureUnknown22Rando G<h4>Background</h4>Hip Osteoarthitis (OA) risk is sport-specific and depends on frequency, intensity, and type of mechanic stress the hip is subjected to. This retrospective observational study aims to investigate the safety and performance of Hymovis (HYADD-4) injection, a hexadecyl (C-16) HA-derivative, when used to manage symptomatic hip OA in active middle-aged sportsmen over a 24-month observation period.<h4>Methods</h4>The retrospective analysis included clinical records of active sportsmen, aged between 40 and 65 years, and suffering from symptomatic Kellgren-Lawrence grade II to III hip OA, treated with two (24 mg/3 ml) Hymovis injections, two weeks apart, every 3-4 months, for two years. When available, data on MRI examination were included in the analysis as well as Heidelberg SpJournal of clinical orthopaedics and trauma101594https://www.ebi.ac.uk/biostudies/studies/S-EPMC8463867biostudies-literatureIntra-articular Hymovis injection for managing hip OA in active sportsmen. A 24-month observational retrospective clinical investigation.PMC8463867Rando GPastorino RfalseIntra-articular Hymovis injection for managing hip OA in active sportsmen. A 24-month observational retrospective clinical investigation.<h4>Background</h4>Hip Osteoarthitis (OA) risk is sport-specific and depends on frequency, intensity, and type of mechanic stress the hip is subjected to. This retrospective observational study aims to investigate the safety and performance of Hymovis (HYADD-4) injection, a hexadecyl (C-16) HA-derivative, when used to manage symptomatic hip OA in active middle-aged sportsmen over a 24-month observation period.<h4>Methods</h4>The retrospective analysis included clinical records of active sportsmen, aged between 40 and 65 years, and suffering from symptomatic Kellgren-Lawrence grade II to III hip OA, treated with two (24 mg/3 ml) Hymovis injections, two weeks apart, every 3-4 months, for two years. When available, data on MRI examination were included in the analysis as well as Heidelberg Sp2021-01-01T00:00:00Z2021 Nov2025-04-04T09:37:42.612Z2025-04-04T09:37:42.612ZS-EPMC84638673460395510.1016/j.jcot.2021.101594